Pfizer
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Pfizer generated cash of $8,700,000,000, which is less than the previous year. Cash used in financing activities reached the amount of $26,066,000,000 last year. Net change in cash is therefore $2,449,000,000.
Cash Flow
| 2014 | 16.88B | -5.65B | -9.98B |
|---|---|---|---|
| 2015 | 14.51B | -2.98B | -10.23B |
| 2016 | 15.90B | -7.81B | -8.92B |
| 2017 | 16.47B | -4.74B | -13.03B |
| 2018 | 15.82B | 4.52B | -20.44B |
| 2019 | 12.58B | -3.94B | -8.48B |
| 2020 | 14.40B | -4.27B | -9.64B |
| 2021 | 32.58B | -22.54B | -9.81B |
| 2022 | 29.26B | -15.78B | -14.83B |
| 2023 | 8.7B | -32.27B | 26.06B |
PFE Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 468M | 1.98B | 1.82B | 1.35B | 1.22B | 1.43B | 2.59B | 3.64B | 3.34B | 2.18B |
Operating activities | ||||||||||
Net income | 2.17B | 31.40B | 22.45B | 7.02B | 16.30B | 11.18B | 21.35B | 7.24B | 6.98B | 9.16B |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 6.29B | 5.06B | 5.19B | 4.77B | 6.01B | 6.38B | 6.26B | 5.75B | 5.15B | 5.53B |
Stock-based compensation expense | 525M | 872M | 1.18B | 756M | 718M | 949M | 840M | 691M | 669M | 586M |
| Deferred income tax benefit | 525M | 872M | 1.18B | 756M | 718M | 949M | 840M | 691M | 669M | 586M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 347M | 261M | -3.81B | -1.24B | -742M | -644M | 259M | -134M | 21M | 148M |
Inventories | 6.19B | 592M | -1.12B | -736M | -1.05B | -717M | -357M | 365M | -199M | 175M |
Accounts payable | -300M | 1.19B | 1.24B | 353M | -564M | 431M | 46M | 871M | 254M | 297M |
Cash generated by operating activities | 8.7B | 29.26B | 32.58B | 14.40B | 12.58B | 15.82B | 16.47B | 15.90B | 14.51B | 16.88B |
Investing activities | ||||||||||
Purchases Of Investments | -31.17B | -38.78B | -47.61B | -14.40B | -7.03B | -13.47B | -18.13B | -28.18B | -38.12B | -61.67B |
Investments In Property Plant And Equipment | -3.90B | -3.23B | -2.71B | -2.79B | -2.59B | -2.19B | -2.21B | -1.99B | -1.49B | -1.58B |
Acquisitions Net | -43.43B | -22.99B | -12M | -621M | -10.86B | 154M | -1B | -18.36B | -16.46B | -195M |
Cash generated by investing activities | -32.27B | -15.78B | -22.54B | -4.27B | -3.94B | 4.52B | -4.74B | -7.81B | -2.98B | -5.65B |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 0 | 9.94B | 0 | 19.46B | 0 | 5.50B |
Payments for dividends | -9.24B | -8.98B | -8.72B | -8.44B | -8.04B | -7.97B | -7.65B | -7.31B | -6.94B | -6.60B |
Repurchases of common stock | 0 | -2B | 0 | 0 | -8.86B | -12.19B | -5B | -5B | -6.16B | -5B |
Repayments of term debt | 35.94B | -3.51B | -2.1B | -30.32B | 8.76B | -9.62B | -941M | -15.87B | 1.31B | -3.95B |
Cash used in financing activities | 26.06B | -14.83B | -9.81B | -9.64B | -8.48B | -20.44B | -13.03B | -8.92B | -10.23B | -9.98B |
Net Change In Cash | 2.44B | -1.51B | 158M | 475M | 125M | -206M | -1.25B | -1.04B | 298M | 1.16B |
Cash at end of period | 2.91B | 468M | 1.98B | 1.82B | 1.35B | 1.22B | 1.34B | 2.59B | 3.64B | 3.34B |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |